title: Oxane HD and retinal detachment surgery in routine clinical practice.
abstract: OBJECTIVE
  To assess the outcomes and complications of endotamponade with Oxane HD following retinal detachment repair.
  
  
  METHODS
  Retrospective consecutive case series of inferior retinal detachment with Oxane HD endotamponade within a 3-year period.
  
  
  RESULTS
  Case notes for 18 eyes of 18 patients were reviewed. Four (22.2%) were total retinal detachments and 13 (72.2%) had proliferative vitreoretinopathy. The mean Oxane HD endotamponade and follow-up durations were 27 ± 38 and 66 ± 39 weeks, respectively. The eventual anatomic success rate was 77.8%, but without any significant difference in vision. Postoperative complications occurred in 14 (77.8%), including emulsification (6 eyes; 33.3%), epiretinal membrane (5 eyes; 27.8%), and posterior capsular opacification (4 eyes; 22.2%). Of the 14 eyes requiring intraoperative perfluorodecalin, 12 (85.7%) developed complications; all 5 (100%) eyes with direct exchange of perfluorodecalin with Oxane HD developed complications.
  
  
  CONCLUSIONS
  Although useful for inferior retinal detachments, Oxane HD was associated with a relatively high rate of emulsification when compared to other series. Our series also suggests that prior use of perfluorodecalin intraoperatively, and in particular direct exchange of perfluorodecalin with Oxane HD, may be associated with an increased risk of intraocular complications.
authors.affiliation: Department of Ophthalmology, Aberdeen Royal Infirmary, Aberdeen, UK.
authors.forename: Ghee Soon
authors.initials: GS
authors.lastname: Ang
authors.forename: Anna Louise
authors.initials: AL
authors.lastname: Murphy
authors.forename: Wai Siene
authors.initials: WS
authors.lastname: Ng
authors.forename: Hatem Riad
authors.initials: HR
authors.lastname: Atta
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005466:Fluorocarbons / Q000008:administration & dosage / Q000009:adverse effects; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D007430:Intraoperative Care; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology; D012163:Retinal Detachment / Q000150:complications / Q000503:physiopathology / Q000601:surgery*; D012189:Retrospective Studies; D018570:Risk Assessment; D012827:Silicone Oils / Q000008:administration & dosage*; D016896:Treatment Outcome; D014792:Visual Acuity; D014821:Vitrectomy / Q000009:adverse effects / Q000379:methods*; D018630:Vitreoretinopathy, Proliferative / Q000150:complications; D014822:Vitreous Body; D055815:Young Adult
chemical_list: D005466:Fluorocarbons; D012827:Silicone Oils; C539721:oxane HD; C008805:perfluorodecalin